积石成山丨上海交通大学附属胸科医院陆舜教授团队代表性论著阶段汇总

临床试验类

Lancet Oncol First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised,  open-label, phase 3 trial Shun Lu（2021）

Lung Cancer Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer: 2-year follow-up from a randomized, open-label, phase 3 study (CheckMate 078) Shun Lu (2020)

Clin Cancer Res Clonal architecture of EGFR mutation predicts the efficacy of EGFR-Tyrosine Kinase Inhitors in advanced NSCLC: a prospective multicenter study (NCT03059641) Shun Lu (2020)

Lung Cancer A phase III, randomized, double-blind, placebo-controlled, multicenter study of fruquintinib in Chinese patients with advanced nonsquamous non-small-cell lung cancer-the FALUCA study Shun Lu (2020)
Lancet Respir Med  Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial  Shun Lu (2020)

Transl Lung Cancer Res  Biosimilar candidate IBI305 plus paclitaxel/carboplatin for the treatment of non-squamous non-small cell lung cancer  Shun Lu (2020)

Front Oncol  A randomized phase III study of Abemaciclib versus Erlotinib in patients with stage IV non-small cell lung cancer with a detectable KRAS mutation who failed prior Platinum-based therapy: JUNIPER  Shun Lu (2020)

J Thorac Oncol Salvage therapy for locoregional recurrence after stereotactic ablative radiotherapy for early-stage non-small cell lung cancer Shun Lu (2020)

J Thorac Oncol Safety, Efficacy and pharmacokinetics of almonertinib (HS-10296) in pretreated patients with EGFR-mutated advanced NSCLC: a multicenter, open-label, phase I trial Shun Lu (2020)

Lancet Respir Med Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial  Shun Lu (2020)

N Engl J Med Osimertinib in resected EGFR-mutated non-small-cell lung cancer   Shun Lu (2020)

J Thorac Oncol Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced NSCLC: CheckMate 078 randomized phase III clinical trial  Shun Lu (2019)

Lung Cancer Erlotinib versus gemcitabine/cisplatin in Chinese patients with EGFR mutation-positive advanced non-small-cell lung cancer: Crossover extension and post-hoc analysis of the ENSURE study Shun Lu (2019)

Lung Cancer  First-line afatinib for advanced EGFRm+ NSCLC: Analysis of long-term responders in the LUX-Lung 3, 6, and 7 trials Shun Lu (2019)

J Thorac Oncol The unique spatial-temporal treatment failure patterns of adjuvant Gefitinib Therapy: A Post Hoc  analysis of the ADJUVANT trial (CTONG 1104)  Mei-lin Liao (2018)

Onco Targets Ther Afatinib versus gemcitabine/cisplatin for first-line treatment of Chinese patients with advanced non-small-cell lung cancer harboring EGFR mutations: subgroup analysis of the LUX-Lung 6 trial  Shun Lu (2018)

Lung Cancer  Clinical utility of a blood-based EGFR mutation test in patients receiving first-line erlotinib therapy in the ENSURE, FASTACT-2, and ASPIRATION studies  Shun Lu (2018)

J Clin Oncol  Randomized, double-blind, placebo-controlled, multicenter phase II study of fruquintinib after two prior chemotherapy regimens in Chinese patients with advanced nonsquamous non-small-cell lung cancer  Shun Lu (2018)

J Thorac Oncol  Nedaplatin plus docetaxel versus cisplatin plus docetaxel as first-line chemotherapy for advanced squamous cell carcinoma of the lung-A multicenter, open-label, randomized, phase III trial Shun Lu (2018)

J Thorac Oncol Results of PROFILE 1029, a phase III comparison of first-line crizotinib versus chemotherapy in East Asian patients with ALK-Positive advanced non-small cell lung cancer Shun Lu (2018)

JAMA Oncol  Association of ERBB mutations with clinical outcomes of afatinib-or erlotinib-treated patients with lung squamous cell carcinoma secondary analysis of the LUX-Lung 8 randomized clinical trial  Shun Lu (2018)

J Clin Oncol  Phase II study of crizotinib in East Asian patients with ROS1-positive advanced non-small-cell lung cancer  Shun Lu (2018)

Lung Cancer Evaluation of the VeriStrat® serum protein test in patients with advanced squamous cell carcinoma of the lung treated with second-line afatinib or erlotinib in the phase III LUX-Lung 8 study Shun Lu (2017)

Ann Oncol Randomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (East Asia S-1 Trial in Lung Cancer)  Shun Lu (2017)

J Thorac Oncol  Results of PROFILE 1029, a phase III comparison of first-line Crizotinib versus chemotherapy in East Asian patients with ALK-positive advanced non-small cell lung cancer  Shun Lu (2017)

Ann Oncol  Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials  Shun Lu (2016)

Ann  Oncol  Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial  Shun Lu (2016)

Lancet Oncol Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung7): a phase 2B, open-label, randomized controlled trial  Shun Lu (2016)

Br J Cancer  EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6  Shun Lu (2016)

Lancet Respir Med  Icotinib versus whole-brain irradiation in patients with EGFR-mutant non-small-cell lung cancer and multiple brain metastases (BRAIN): a multicenter, phase 3, open-label, parallel, randomised controlled trial  Shun Lu (2016)

Asia-Pacific J Clin Oncol  An East Asian subgroup analysis of PROCLAIM, a phase III trial of pemetrexed and cisplatin or etoposide and cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous non-small cell lung cancer  Shun Lu (2016)

Lancet Oncol  Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial  Mei-lin Liao (2016)

J Thorac Oncol A multicenter, open-label, randomized phase II controlled study of rh-Endostatin (Endostar) in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer Shun Lu (2015)

Lancet Oncol  Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial  Shun Lu (2015)

Lancet Oncol Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials  Shun Lu (2015)

Ann Oncol First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study  Shun Lu (2015)

Ann Oncol Final overall survival results from a randomised, Phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802) Shun Lu (2015)

Ann Oncol  Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial  Shun Lu (2015)

J Thorac Oncol  Final overall survival results from a phase III, randomized,

placebo-controlled, parallel-group study of gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804)  Shun Lu (2015)

J Thorac Oncol  Symptom and quality of life improvement in LUX-Lung 6: An open-label phase III study of afatinib versus cisplatin/gemcitabine in Asian patients with EGFR mutation-positive advanced non-small cell lung cancer  Shun Lu (2015)

Jpn J Clin Oncol  Efficacy of erlotinib in previously treated patients with advanced non-small cell lung cancer: analysis of the Chinese subpopulation in the TRUST study Mei-lin Liao (2015)

Eur J Cancer Analysis of patient-reported outcomes from the LUME-Lung 1 trial: a randomised, double-blind, placebo-controlled, Phase III study of second-line nintedanib in patients with advanced non-small cell lung cancer  Mei-lin Liao (2015)

Clin Cancer Res  Detection and dynamic changes of EGFR mutations from circulating tumor DNA as a predictor of survival outcomes in NSCLC patients treated with first-line intercalated Erlotinib and chemotherapy Mei-lin Liao (2015)

Lancet Oncol Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial  Mei-Lin Liao (2014)

J Clin Oncol BEYOND: A randomized, double-blind, placebo-controlled, multicenter, phase III study of first-line carboplatin/paclitaxel plus bevacizumab or placebo in Chinese patients with advanced or recurrent nonsquamous non-small-cell lung cancer  Shun Lu (2014)

Lung Cancer Efficacy and safety of pemetrexed/cisplatin versus gemcitabine/cisplatin as first-line treatment in Chinese patients with advanced nonsquamous non-small cell lung cancer  Shun Lu (2014)

Lancet Oncol  Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial Shun Lu (2014)

Lancet Oncol  Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial  Mei-Lin Liao (2013)

Ann Oncol  Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and a symptomatic brain metastases: a phase II study (CTONG-0803)  Shun Lu (2013)

Asia-Pacific J Clin Oncol  Phase III, randomized, open-label, first-line study in Asia of gefitinib versuscar boplatin/paclitaxel in clinically selected patients with advanced non-small-cell  lung cancer: evaluation of patients recruited from China  Mei-Lin Liao (2012)

J Clin Oncol Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer Mei-Lin Liao (2012)

Lancet Oncol Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trial  Shun Lu (2012)

Lancet Oncol  Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study  Shun Lu (2011)

J Thorac Oncol Health-related quality-of-life in a randomized phase III first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS) Mei-lin Liao (2011)

J Clin Oncol Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial  Mei-lin Liao (2010)

J Clin Oncol  Randomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small-cell lung cancer  Mei-lin Liao (2009)

Lancet  Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial   Mei-lin Liao (2008)

Chin Med J Gemcitabine and cisplatin treatment over a 3-week versus a 4-week dosing schedule: a randomized trial conducted in Chinese patients with nonsmall cell lung cancer  Mei-lin Liao (2008)

转化研究类

Transl Lung Cancer Res The effect of PD-L1 categories-directed pembrolizumab plus chemotherapy for newly diagnosed metastatic non-small-cell lung cancer: a cost-effectiveness analysis  Shun Lu (2021)

Transl Lung Cancer Res  Circulating tumor DNA clearance predicts prognosis across treatment regimen in a large real-world longitudinally monitored advanced non-small cell lung cancer cohort Shun Lu (2020)

Oncogenesis Reciprocal regulatory mechanism between miR-214-3p and FGFR1 in FGFR1-amplified lung cancer Shun Lu (2019)

EBioMedicine Value of folate receptor-positive circulating tumor cells in the clinical management of indeterminate lung nodules: A non-invasive biomarker for predicting malignancy and tumor invasiveness Shun Lu (2019)

J Thorac Oncol The diversity of gut microbiome is associated with favorable responses to anti-PD-1 immunotherapy in Chinese non-small cell lung cancer patients  Shun Lu (2019)

Nat Commun Liquid biopsy-based single-cell metabolic phenotyping of lung cancer patients for informative diagnostics Shun Lu (2019)

J Thorac Oncol EGFR and ERBB2 germline mutations in Chinese lung cancer patients and their roles in genetic susceptibility to cancer Shun Lu (2019)

J Thorac Oncol Durable clinical response of lung adenocarcinoma harboring EGFR 19del/T790M/in trans-C797S to combination therapy of first-and third-generation EGFR TKIs Shun Lu (2019)

Oncogene FGFR1-ERK1/2-SOX2 axis promotes cell proliferation, epithelial–mesenchymal transition, and metastasis in FGFR1-amplified lung cancer Shun Lu (2018)

J Thorac Oncol  Efficacy of crizotinib among different types of ROS1 fusion partners in patients with ROS1-rearranged non-small-cell lung cancer Shun Lu (2018)

Cancer Commun  Xenograft tumors derived from malignant pleural effusion of the patients with non‑small‑cell lung cancer as models to explore drug resistance  Shun Lu (2018)

Cancer Lett The Hippo/YAP1 pathway interacts with FGFR1 signaling to maintain stemness in lung cancer  Shun Lu (2018)

J Exp Clin Cancer Res  SIRT6 drives epithelial-to-mesenchymal transition and metastasis in non-small cell lung cancer via snail-dependent transrepression of KLF4 Shun Lu (2018)

J Exp Clin Cancer Res  FGF2/FGFR1 regulates autophagy in FGFR1-amplified non-small cell lung cancer cells Shun Lu (2017)

P Natl Acad Sci USA  High-throughput screening of rare metabolically active tumor cells in pleural effusion and peripheral blood of lung cancer patients Shun Lu (2017)

Clin Cancer Res  Genome-wide DNA methylation analysis reveals GABBR2 as a novel epigenetic target for EGFR 19 deletion lung adenocarcinoma with induction erlotinib treatment  Shun Lu (2017)

J Cell Mol Med 17-AAG suppresses growth and invasion of lung adenocarcinoma cells via regulation of the LATS1/YAP pathway Shun Lu (2015)

Clin Cancer Res TERT polymorphism rs2736100-C is associated with EGFR mutation-positive non-small cell lung cancer Shun Lu (2015)
Br J Pharmacol  hMOF acetylates Nrf2 and regulates anti-drug responses in human non-small cell lung caner Shun Lu (2014)

Chest Prognostic significance of the extent of lymph node involvement in stage II-N1 non-small cell lung cancer  Shun Lu (2012)

J Thorac Oncol A study of ethnic differences in TGFβ1 gene polymorphisms and effects on the risk of radiation pneumonitis in non-small-cell lung cancer Shun Lu (2012)

J Thorac Oncol  Association of the CHRNA3 locus with lung cancer risk and prognosis in Chinese Han population  Shun Lu (2010)

J Thorac Oncol Analysis of the T descriptors and other prognosis factorsin pathologic stage I non-small cell lung cancer in China  Shun Lu (2010)

推荐阅读

肺癌系列文章汇总 (2021年1月)肺癌，临床试验招募汇总整理者